/
CRBP
$8.98+$0.24 (+2.75%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$161.9M
19M shares
52-week range
$6.72 – $20.56
16% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-45.62
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.8M | $36.1M | $3.9M | $881.7K | $0 | $0 | $0 | $0 |
| Cost of revenue | $48.6M | $89.6M | $0 | $1.6M | $1.5M | $0 | $600.0K | $0 |
| Gross profit | −$43.8M | −$53.5M | $3.9M | −$757.5K | −$1.5M | $0 | −$600.0K | $0 |
| Gross margin | -908.1% | -147.9% | 100.0% | -85.9% | — | — | — | — |
| R&D | $48.6M | $89.6M | $98.3M | $36.4M | $16.1M | $31.2M | $32.2M | $70.1M |
| Operating income | −$56.7M | −$77.1M | −$122.8M | −$56.0M | −$34.8M | −$45.1M | −$48.7M | −$85.3M |
| EBITDA | −$56.3M | −$76.4M | −$121.1M | −$42.2M | −$38.7M | −$40.1M | −$37.7M | −$78.3M |
| Net income | −$55.7M | −$71.5M | −$111.3M | −$45.6M | −$55.8M | −$44.6M | −$40.2M | −$78.5M |
| Net margin | -1154.5% | -197.7% | -2826.1% | -5166.4% | — | — | — | — |
| EPS (diluted) | -29.30 | -33.55 | -42.72 | -11.13 | -10.15 | -10.31 | -3.68 | -5.90 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-4.64 | $-5.43–$-3.15 | 8 |
| 2027 | $4M | $-5.15 | $-5.96–$-4.34 | 7 |
| 2028 | $5M | $-5.49 | $-7.34–$-3.01 | 8 |
| 2029 | $74M | $-4.55 | $-4.55–$-4.55 | 6 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.97
Price
$8.98
Implied downside
-78%
Peer comparison
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
www.corbuspharma.com- Employees
- 36
- IPO / List date
- Oct 24, 2014
- HQ
- NORWOOD, MA
Held by traders on TradeandTell
No one on the platform currently holds CRBP.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 346,998 | $3.3M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-02-14 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded CRBP yet.
